DK2101569T3 - Krystallinsk fast rasagilinbase - Google Patents

Krystallinsk fast rasagilinbase

Info

Publication number: DK2101569T3
Authority: DK; Denmark
Prior art keywords: crystalline solid; rasagiline base; solid rasagiline; base; aminoindan
Prior art date: 2006-12-14

Application number

DK07862906.0T

Other languages

English (en)

Inventor

Anton Frenkel

Tamas Koltai

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-14

Filing date

2007-12-13

Publication date

2012-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39536623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2101569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-13 Application filed by Teva Pharma filed Critical Teva Pharma

2012-01-30 Application granted granted Critical

2012-01-30 Publication of DK2101569T3 publication Critical patent/DK2101569T3/da

Links

RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title 1
229960000245 rasagiline Drugs 0.000 title 1
239000007787 solid Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

DK07862906.0T 2006-12-14 2007-12-13 Krystallinsk fast rasagilinbase DK2101569T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87501106P	2006-12-14	2006-12-14
PCT/US2007/025583 WO2008076348A1 (en)	2006-12-14	2007-12-13	Crystalline solid rasagiline base

Publications (1)

Publication Number	Publication Date
DK2101569T3 true DK2101569T3 (da)	2012-01-30

Family

ID=39536623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07862906.0T DK2101569T3 (da)	2006-12-14	2007-12-13	Krystallinsk fast rasagilinbase

Country Status (24)

Country	Link
US (4)	US7750051B2 (da)
EP (1)	EP2101569B1 (da)
JP (1)	JP5623081B2 (da)
KR (1)	KR101459744B1 (da)
CN (1)	CN101557706B (da)
AT (1)	ATE528989T1 (da)
AU (1)	AU2007334428B2 (da)
CA (1)	CA2672414A1 (da)
CY (1)	CY1112511T1 (da)
DK (1)	DK2101569T3 (da)
EA (1)	EA016820B1 (da)
ES (1)	ES2375761T3 (da)
HR (1)	HRP20110980T1 (da)
IL (1)	IL198985A0 (da)
MX (1)	MX2009006251A (da)
NO (1)	NO20092611L (da)
NZ (1)	NZ577460A (da)
PL (1)	PL2101569T3 (da)
PT (1)	PT2101569E (da)
RS (1)	RS52183B (da)
SI (1)	SI2101569T1 (da)
UA (1)	UA97502C2 (da)
WO (1)	WO2008076348A1 (da)
ZA (1)	ZA200903903B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006014973A2 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) *	2004-11-24	2009-04-30	Shulamit Patashnik	Rasagiline Orally Disintegrating Compositions
PL1848415T3 (pl) *	2005-02-17	2013-10-31	Teva Pharma	Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
WO2006091657A1 (en)	2005-02-23	2006-08-31	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
CA2630037C (en) *	2005-11-17	2015-03-31	Teva Pharmaceutical Industries Ltd.	Methods for isolating propargylated aminoindans
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
ES2551481T3 (es)	2006-02-21	2015-11-19	Teva Pharmaceutical Industries, Ltd.	Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) *	2006-04-03	2015-08-26	テバファーマシューティカルインダストリーズリミティド	レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh)	2006-12-14	2013-08-07	泰华制药工业有限公司	雷沙吉兰碱结晶固体
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) *	2007-09-05	2009-03-12	Teva Pharmaceutical Industries Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) *	2008-01-11	2013-01-23	Teva Pharma	RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
EP2285769B1 (en)	2008-06-02	2014-08-13	Generics [UK] Limited	A process for the preparation of enantiomerically pure amines
WO2009151594A1 (en) *	2008-06-10	2009-12-17	Teva Pharmaceutical Industries, Ltd.	Rasagiline soft gelatin capsules
MX2010013766A (es) *	2008-06-13	2011-03-15	Teva Pharmaceutical Ind Ltd Star	Rasagilina para modificacion de enfermedad de parkinson.
US8334409B2 (en) *	2008-06-19	2012-12-18	Teva Pharmaceutical Industries, Ltd.	Process for purifying rasagiline base
BRPI0909997A2 (pt)	2008-06-19	2015-10-27	Teva Pharma	r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
CN101606923B (zh) *	2008-06-20	2013-01-09	重庆医药工业研究院有限责任公司	一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
ITMI20081406A1 (it) *	2008-07-29	2010-01-30	Dipharma Francis Srl	Forma cristallina di rasagilina e procedimento per la sua preparazione
EP2358658A4 (en)	2008-11-20	2012-11-14	Reddys Lab Ltd Dr	PREPARATION OF RASAGILIN AND ITS SALTS
EP2218444A3 (en)	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
US20100189791A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
SI2451771T1 (sl)	2009-07-09	2014-10-30	Ratiopharm Gmbh	Soli rasagilina in njihovi farmacevtski pripravki
EP2298277A1 (en) *	2009-09-09	2011-03-23	Labtec GmbH	Transdermal patch formulation
CN102048717B (zh)	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2325159A1 (en)	2009-11-24	2011-05-25	LEK Pharmaceuticals d.d.	Novel salts of rasagiline
EP2515891A4 (en) *	2009-12-22	2013-06-05	Teva Pharma	3-keto-N-propargyl-1-aminoindan
WO2011121607A2 (en)	2010-03-29	2011-10-06	Cadila Healthcare Limited	Rasagiline and its pharmaceutically acceptable salts
MX2012012069A (es)	2010-04-30	2012-11-22	Teikoku Pharma Usa Inc	Composiciones transdermicas de propinilaminoindan.
AU2011282720B2 (en)	2010-07-27	2016-12-22	Teva Pharmaceutical Industries Ltd.	Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja)	2010-07-27	2013-10-03	テバファーマシューティカルインダストリーズリミティド	ラサギリンシトレートの分散物
KR101853082B1 (ko)	2011-03-24	2018-04-27	테이코쿠 팔마 유에스에이, 인코포레이티드	활성제층 및 활성제 변환층을 포함하는 경피 조성물
EP2705021A2 (en)	2011-05-04	2014-03-12	Cadila Healthcare Limited	Rasagiline and its pharmaceutically acceptable salts
HK1200315A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	R(+)-n-formyl-propargyl-aminoindan
JP2014534197A (ja)	2011-10-10	2014-12-18	テバファーマシューティカルインダストリーズリミティド	Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
JP5913614B2 (ja)	2011-11-09	2016-04-27	テイコクファーマユーエスエーインコーポレーテッド	皮膚新生物の処置方法
EP2610239A1 (en)	2012-01-02	2013-07-03	Dr. Reddy's Laboratories Ltd.	Preparation Of Rasagiline Hemitartrate
EA201491734A1 (ru)	2012-03-21	2015-01-30	Синтон Бв	Стабилизированные фармацевтические композиции, содержащие соли разагилина
JP2015529196A (ja)	2012-08-17	2015-10-05	テバファーマシューティカルインダストリーズリミティド	ラサギリンの非経口製剤
JP6050896B2 (ja)	2012-11-02	2016-12-21	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダン経皮組成物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4252951A (en) *	1979-10-09	1981-02-24	Eli Lilly And Company	Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US4529811A (en) *	1981-03-02	1985-07-16	G. D. Searle & Co.	Process for isolating organic compounds and lithium salt complexes useful in said process
IL92952A (en) *	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CN1031995C (zh) *	1991-01-02	1996-06-12	奥韦特有限公司	N-炔丙基-1-氨基茚满的r-对映体的制法
IL99759A (en) *	1991-10-16	1997-06-10	Teva Pharma	Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en)	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5877218A (en)	1994-01-10	1999-03-02	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
PT807101E (pt)	1995-02-01	2001-12-28	Upjohn Co	2-aminoindanos comoligandos selectivos de dopamina d3
IL115357A (en) *	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) *	1996-06-28	1997-09-02	Jame Fine Chemicals, Inc.	Process for preparing antihistamine tannates
IL118836A (en) *	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ES2241064T3 (es) *	1996-12-18	2005-10-16	Teva Pharmaceutical Industries, Ltd.	Derivados de aminoindano.
US7150881B2 (en)	1997-06-26	2006-12-19	Mylan Technologies, Inc.	Adhesive mixture for transdermal delivery of highly plasticizing drugs
AU2472499A (en) *	1998-01-27	1999-08-09	Thomas N. Thomas	Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
DE10041478A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
IL141690A (en) *	2001-02-27	2004-06-20	Isp Finetech Ltd	Process for preparation of rasagiline and its salts
US6543155B2 (en)	2001-03-01	2003-04-08	National Agricultural Research Organization	Freeze-dried product and process and apparatus for producing it
EP1441708B1 (en) *	2001-11-05	2009-04-08	Krele Pharmaceuticals LLC	Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US20050239054A1 (en) *	2002-04-26	2005-10-27	Arimilli Murty N	Method and compositions for identifying anti-HIV therapeutic compounds
US20040166159A1 (en) *	2002-05-29	2004-08-26	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
UA78854C2 (en) *	2002-09-06	2007-04-25	Kissei Pharmaceutical	Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
ES2432117T3 (es) *	2002-11-15	2013-11-29	Teva Pharmaceutical Industries Limited	Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
US20040157784A1 (en) *	2003-02-10	2004-08-12	Jame Fine Chemicals, Inc.	Opiod tannate compositions
JP5460947B2 (ja) *	2003-09-03	2014-04-02	グラクソグループリミテッド	新規調製方法、塩、組成物及び使用
US7799273B2 (en)	2004-05-06	2010-09-21	Smp Logic Systems Llc	Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
WO2006014973A2 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) *	2004-11-24	2009-04-30	Shulamit Patashnik	Rasagiline Orally Disintegrating Compositions
ATE521343T1 (de)	2004-11-24	2011-09-15	Teva Pharma	Im mund zerfallende zusammensetzungen von rasagilin
WO2006091657A1 (en) *	2005-02-23	2006-08-31	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
CA2630037C (en) *	2005-11-17	2015-03-31	Teva Pharmaceutical Industries Ltd.	Methods for isolating propargylated aminoindans
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
US7572834B1 (en) *	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
ES2551481T3 (es) *	2006-02-21	2015-11-19	Teva Pharmaceutical Industries, Ltd.	Uso de rasagilina para el tratamiento de atrofia multisistémica
CN101032474B (zh)	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
JP5769923B2 (ja) *	2006-04-03	2015-08-26	テバファーマシューティカルインダストリーズリミティド	レストレスレッグス症候群の治療のためのラサギリンの使用
US7573834B2 (en) *	2006-05-31	2009-08-11	Alcatel Lucent	Method and system for allocating a group bit rate among multiple bonded pairs in a communications network
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
CN101600346B (zh) *	2006-12-14	2013-08-21	泰华制药工业有限公司	雷沙吉兰的单宁酸盐
CN101557706B (zh)	2006-12-14	2013-08-07	泰华制药工业有限公司	雷沙吉兰碱结晶固体
EP1987816A1 (de)	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) *	2007-09-05	2009-03-12	Teva Pharmaceutical Industries Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) *	2008-01-11	2013-01-23	Teva Pharma	RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
US20110117200A1 (en)	2008-03-31	2011-05-19	Actavis Group Ptc Ehf	Rasagiline mesylate particles and process for the preparation thereof
WO2009151594A1 (en)	2008-06-10	2009-12-17	Teva Pharmaceutical Industries, Ltd.	Rasagiline soft gelatin capsules
US8334409B2 (en)	2008-06-19	2012-12-18	Teva Pharmaceutical Industries, Ltd.	Process for purifying rasagiline base
BRPI0909997A2 (pt)	2008-06-19	2015-10-27	Teva Pharma	r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
DE102008064061A1 (de) *	2008-12-19	2010-06-24	Ratiopharm Gmbh	Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
SI2451771T1 (sl)	2009-07-09	2014-10-30	Ratiopharm Gmbh	Soli rasagilina in njihovi farmacevtski pripravki
AU2010304755A1 (en) *	2009-10-09	2012-05-24	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) *	2009-12-22	2013-06-05	Teva Pharma	3-keto-N-propargyl-1-aminoindan
JP2013537530A (ja) *	2010-07-27	2013-10-03	テバファーマシューティカルインダストリーズリミティド	ラサギリンシトレートの分散物
AU2011282720B2 (en) *	2010-07-27	2016-12-22	Teva Pharmaceutical Industries Ltd.	Use of rasagiline for the treatment of olfactory dysfunction
SG189454A1 (en)	2010-10-26	2013-05-31	Teva Pharma	Deuterium enriched rasagiline
AU2012323346A1 (en) *	2011-10-10	2014-05-15	Teva Pharmaceutical Industries Ltd	Rasagiline citramide
HK1200315A1 (en) *	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	R(+)-n-formyl-propargyl-aminoindan
JP2014534197A (ja) *	2011-10-10	2014-12-18	テバファーマシューティカルインダストリーズリミティド	Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン

2007
- 2007-12-13 CN CN2007800458662A patent/CN101557706B/zh not_active Expired - Fee Related
- 2007-12-13 AU AU2007334428A patent/AU2007334428B2/en not_active Ceased
- 2007-12-13 DK DK07862906.0T patent/DK2101569T3/da active
- 2007-12-13 WO PCT/US2007/025583 patent/WO2008076348A1/en not_active Ceased
- 2007-12-13 US US12/002,082 patent/US7750051B2/en not_active Expired - Fee Related
- 2007-12-13 KR KR1020097014006A patent/KR101459744B1/ko not_active Expired - Fee Related
- 2007-12-13 SI SI200730807T patent/SI2101569T1/sl unknown
- 2007-12-13 NZ NZ577460A patent/NZ577460A/en unknown
- 2007-12-13 MX MX2009006251A patent/MX2009006251A/es active IP Right Grant
- 2007-12-13 ES ES07862906T patent/ES2375761T3/es active Active
- 2007-12-13 UA UAA200906360A patent/UA97502C2/ru unknown
- 2007-12-13 AT AT07862906T patent/ATE528989T1/de active
- 2007-12-13 PT PT07862906T patent/PT2101569E/pt unknown
- 2007-12-13 RS RS20120016A patent/RS52183B/sr unknown
- 2007-12-13 PL PL07862906T patent/PL2101569T3/pl unknown
- 2007-12-13 ZA ZA200903903A patent/ZA200903903B/xx unknown
- 2007-12-13 EP EP07862906A patent/EP2101569B1/en active Active
- 2007-12-13 EA EA200970581A patent/EA016820B1/ru not_active IP Right Cessation
- 2007-12-13 CA CA002672414A patent/CA2672414A1/en not_active Abandoned
- 2007-12-13 HR HR20110980T patent/HRP20110980T1/hr unknown
- 2007-12-13 JP JP2009541390A patent/JP5623081B2/ja not_active Expired - Fee Related
2009
- 2009-05-27 IL IL198985A patent/IL198985A0/en unknown
- 2009-07-08 NO NO20092611A patent/NO20092611L/no not_active Application Discontinuation
2010
- 2010-01-08 US US12/655,827 patent/US8614252B2/en not_active Expired - Fee Related
- 2010-01-08 US US12/655,828 patent/US20100144887A1/en not_active Abandoned
2012
- 2012-01-11 CY CY20121100022T patent/CY1112511T1/el unknown
2014
- 2014-08-14 US US14/459,877 patent/US20150038744A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20080161408A1 (en)	2008-07-03
NZ577460A (en)	2012-01-12
EP2101569A4 (en)	2009-12-02
CY1112511T1 (el)	2015-12-09
EP2101569B1 (en)	2011-10-19
JP5623081B2 (ja)	2014-11-12
WO2008076348A1 (en)	2008-06-26
ES2375761T3 (es)	2012-03-06
AU2007334428B2 (en)	2014-05-29
US8614252B2 (en)	2013-12-24
EA016820B1 (ru)	2012-07-30
ZA200903903B (en)	2010-08-25
EA200970581A1 (ru)	2009-12-30
HRP20110980T1 (hr)	2012-02-29
US20150038744A1 (en)	2015-02-05
PT2101569E (pt)	2012-01-13
HK1129276A1 (en)	2009-11-27
US20100145101A1 (en)	2010-06-10
IL198985A0 (en)	2010-02-17
CN101557706A (zh)	2009-10-14
US7750051B2 (en)	2010-07-06
US20100144887A1 (en)	2010-06-10
WO2008076348A8 (en)	2008-08-21
PL2101569T3 (pl)	2012-03-30
SI2101569T1 (sl)	2012-02-29
MX2009006251A (es)	2009-10-12
AU2007334428A1 (en)	2008-06-26
NO20092611L (no)	2009-09-11
JP2010513282A (ja)	2010-04-30
CN101557706B (zh)	2013-08-07
UA97502C2 (ru)	2012-02-27
EP2101569A1 (en)	2009-09-23
ATE528989T1 (de)	2011-11-15
RS52183B (sr)	2012-10-31
CA2672414A1 (en)	2008-06-26
KR101459744B1 (ko)	2014-11-20
KR20090089894A (ko)	2009-08-24

Publication	Publication Date	Title
DK2101569T3 (da)	2012-01-30	Krystallinsk fast rasagilinbase
TW200732349A (en)	2007-09-01	Anti-OX40L antibodies and methods using same
JO2778B1 (en)	2014-03-15	Certain Compounds, Compositions and Methods
MX2009006252A (es)	2009-10-13	Sal de tanato de rasagilina.
MX2010002974A (es)	2010-07-29	Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida.
PH12015500550A1 (en)	2016-06-13	Anti-notch1 nrr antibodies and methods using same
HN2006011218A (es)	2008-09-17	Composiciones de tigeciclina y métodos de preparación
HUE042561T2 (hu)	2019-07-29	Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
BR112012014082A2 (pt)	2017-05-23	composições e métodos que compreendem variantes de protease
DK3219705T3 (da)	2020-04-14	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
MX2012007507A (es)	2012-08-01	Compuestos de heteroarilo y usos de los mismos.
MY173526A (en)	2020-01-31	Novel anti-?5?1 antibodies and uses thereof
NO20080991L (no)	2008-05-15	Bazedoksifen acetat formuleringer
WO2008057291A3 (en)	2008-07-03	Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
CY1118976T1 (el)	2018-01-10	Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
EP2644614A3 (en)	2014-02-26	Solid state forms of 5-azacytidine and processes for preparation thereof
UY31103A1 (es)	2009-01-05	Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones
TW200738649A (en)	2007-10-16	Calcilytic compounds
EA200600590A1 (ru)	2006-08-25	Фармацевтические композиции модафинила с модифицированным высвобождением
ATE552832T1 (de)	2012-04-15	Antidepressivum-propharmaka
WO2008015584A3 (en)	2008-06-12	Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
ATE539082T1 (de)	2012-01-15	Oxazinylisoflavonoidverbindungen, medikamente und anwendungen
WO2006091836A8 (en)	2007-04-12	Formulations of ladostigil tartrate
TW200638932A (en)	2006-11-16	CCI-779 polymorph and use thereof
NO20091386L (no)	2009-05-06	Fenyloksyanilinderivater